Document is current

Article History

Received: 26 April 2022

Accepted: 22 September 2022

First Online: 20 October 2022

Declarations

:

: All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The institutional board of Carmel Medical Center reviewed and approved the study protocol, IRB number CMC108-16.Informed consent was obtained from all individual participants included in the study.This article does not contain any studies with animals performed by any of the authors.The ClinicalTrials.gov identifier of the study is NCT04623879.

: Not applicable.

: Author GL received research grant from Vertex Pharmaceuticals for the submitted work.Vertex Pharmaceuticals, did not participate in article preparation, study design, data collection, analysis, or interpretation of data.Author MS declares that she has no conflict of interest regarding the submitted work. Dr. Shteinberg reports grants, personal fees and non-financial support from GSK, grants and personal fees from Novartis, personal fees from Bohringer- Ingelheim, personal fees from Astra Zeneca, personal fees from Kamada, personal fees from Vertex pharmaceuticals, personal fees from Teva, non-financial support from Actelion, grants, personal fees and non-financial support from GSK, grants from Novartis, non-financial support from Rafa, personal fees from Zambon, outside the submitted work.Author KY declares that she has no conflict of interest.Author ZS declares that he has no conflict of interest.Author IK declares that she has no conflict of interest.Author AI declares that she has no conflict of interest.Author MK declares that he has no conflict of interest.Author NS declares that he has no conflict of interest.